MPK20 Antibody

What exactly is MPK20 and why is it significant in research?

MPK20 refers to two distinct proteins in scientific literature that researchers should be careful to differentiate:

• In mammalian systems, KIF20B was originally named M-phase phosphoprotein 1 (MPP1) before nomenclature changes. It is a plus-end-directed kinesin-related protein that exhibits microtubule-binding and -bundling properties with microtubule-stimulated ATPase activity. It functions as a slow molecular motor moving toward the plus-end of microtubules .

• In plant systems, particularly cotton, GhMPK20 is a group D mitogen-activated protein kinase (MAPK) that plays a critical role in plant defense responses, particularly against Fusarium oxysporum .

The significance of these proteins varies by research context. KIF20B/MPP1 has been identified as an autoantigen in up to 25% of patients with idiopathic ataxia and in some patients with demyelinating polyneuropathy, making associated antibodies potentially valuable biomarkers . In contrast, GhMPK20 is critical in understanding plant pathogen resistance mechanisms .

How do MPK20 antibodies function differently from other research antibodies?

Anti-KIF20B (MPP1) antibodies bind to a protein with distinct localization patterns throughout the cell cycle, requiring specialized detection protocols. During interphase, KIF20B localizes primarily in nuclei, but during metaphase, it redistributes throughout the cytoplasm and perichromatin mass. Later in telophase/anaphase, KIF20B concentrates at the stem body and midzone of the midbody .

This dynamic cellular localization pattern distinguishes MPK20 antibodies from many other research antibodies that target proteins with more static cellular distributions. Consequently, researchers must consider cell cycle phase when interpreting immunostaining results, as localization patterns vary significantly depending on mitotic stage .

What are the key structural features of MPK20 that affect antibody development?

KIF20B contains extensive coiled-coil domains that influence epitope accessibility and antibody binding . In developing the monoclonal antibody 10C7, researchers targeted specific epitopes including a synthetic peptide (QPKRAKRKLYTSEISS) that proved effective for generating specific antibodies .

For GhMPK20, the protein participates in specific protein-protein interactions with upstream kinases (like GhMKK4) and downstream transcription factors (such as GhWRKY40). These interaction domains must be considered when developing antibodies to avoid interfering with functional studies of these interactions .

What are the optimal immunoassay conditions for detecting MPK20 in different sample types?

Based on established protocols, the following immunoassay conditions are recommended:

For Western Blot and ALBIA (Addressable Laser Bead Immunoassay):

• The monoclonal antibody 10C7 has demonstrated reliable detection of KIF20B in these formats

• For ALBIA: Use MagPlex microspheres coupled with either full-length recombinant human KIF20B or partial-length proteins (amino acids 1671-1780)

• Positivity thresholds: >500 MFI (Median Fluorescence Intensity) for lysates and >250 MFI for synthetic peptides (three standard deviations above control values)

For Immunofluorescence:

• Cell types with reliable detection: HEp2 cells, leptomeningeal pericytes, and transfected HEK293T cells

• Special considerations: Cell cycle stage significantly affects localization patterns

• Tissue staining: Remarkable staining has been observed in subsets of cells in cerebellum, ovary, and testis tissues

How should I troubleshoot inconsistent MPK20 antibody staining patterns?

When encountering inconsistent staining patterns with MPK20 antibodies, consider:

• Cell Cycle Variability: KIF20B localization changes dramatically through the cell cycle. Synchronize cells or confirm cell cycle stage through co-staining with cell cycle markers .

• Epitope Masking: KIF20B's extensive coiled-coil domains may result in conformational changes that mask epitopes. Try multiple fixation protocols (paraformaldehyde versus methanol) or epitope retrieval methods .

• Expression Level Variability: KIF20B shows tissue and cell-type specific expression. In cerebellum, ovary, and testis, only specific cell subsets show strong staining .

• Cross-reactivity Assessment: Verify antibody specificity using knockout/knockdown controls, particularly when working with novel cell types or tissues .

• Signal Amplification: For tissues with low expression, consider using signal amplification methods like tyramide signal amplification while maintaining appropriate controls.

What controls are essential when using MPK20 antibodies in experimental procedures?

When designing experiments with MPK20 antibodies, implement these critical controls:

Essential Controls for MPK20 Antibody Experiments:

When working with GhMPK20 in plant systems, additional controls include virus-induced gene silencing (VIGS) of GhMPK20 compared to non-silenced tissues to validate antibody specificity .

How can MPK20 antibodies be utilized to investigate signaling pathways in disease models?

MPK20 antibodies offer several sophisticated applications for investigating signaling pathways:

For Neurological Disease Research:
KIF20B autoantibodies have been identified in up to 25% of patients with idiopathic ataxia and in some patients with demyelinating polyneuropathy . Researchers can:

• Use the monoclonal antibody 10C7 as a reference standard to identify and quantify autoantibodies in patient samples

• Investigate the pathogenic mechanisms by which these autoantibodies might interfere with KIF20B function

• Correlate autoantibody levels with disease progression or treatment response

For Plant Pathogen Response Mechanisms:
In plant systems, MPK20 antibodies can elucidate defense signaling pathways:

• Track the activation of the MKK4-MPK20-WRKY40 pathway during pathogen infection

• Compare phosphorylation states of MPK20 before and after pathogen exposure

• Investigate the interactions between MPK20 and downstream targets using co-immunoprecipitation with anti-MPK20 antibodies

What are the methodological considerations when using MPK20 antibodies in co-immunoprecipitation studies?

When designing co-immunoprecipitation (Co-IP) experiments with MPK20 antibodies, researchers should consider:

• Protein Interaction Dynamics: GhMPK20 interacts with both upstream kinases (GhMKK4) and downstream transcription factors (GhWRKY40) . These interactions have been confirmed by multiple methods, including yeast two-hybrid, bimolecular fluorescence complementation (BiFC), and Co-IP studies .

• Tag Selection: When using tagged proteins, consider:

  • For GhMPK20: MYC tags have been successfully used in Co-IP experiments

  • For interaction partners: FLAG tags on GhMKK4 and GhWRKY40 have enabled successful immunoprecipitation with GhMPK20-MYC

• Buffer Optimization:

  • Cell lysis buffers should preserve protein interactions while effectively extracting proteins

  • Consider phosphatase inhibitors to maintain phosphorylation states, particularly important for MAPK pathway studies

  • Detergent concentration should be optimized to solubilize membrane-associated proteins without disrupting interactions

• Validation Methods: Confirm interactions using complementary approaches as demonstrated in the literature:

  • Yeast two-hybrid assays show growth on selective media (SD medium DDO and QDO/X) for genuine interactions

  • BiFC in plant cells shows fluorescence localization in both cytoplasm and nucleus for GhMPK20-GhMKK4 interactions

How can MPK20 antibodies be applied in studying cell cycle dynamics?

MPK20/KIF20B antibodies are particularly valuable for studying cell cycle progression due to the protein's dynamic localization patterns:

• Mitotic Phase Identification:

  • Interphase: KIF20B predominantly localizes to nuclei

  • Metaphase: KIF20B redistributes throughout cytoplasm and perichromatin mass

  • Telophase/anaphase: KIF20B concentrates at the stem body and midzone of the midbody

These distinct localization patterns make anti-KIF20B antibodies useful markers for specific mitotic phases.

• Experimental Approaches:

  • Multi-color immunofluorescence combining anti-KIF20B with other cell cycle markers

  • Live-cell imaging using fluorescently tagged anti-KIF20B antibody fragments

  • Correlative studies between KIF20B localization and microtubule dynamics

• Research Applications:

  • Investigate how disruption of KIF20B affects cytokinesis completion

  • Study the role of KIF20B in organizing microtubules during cell division

  • Examine potential correlations between aberrant KIF20B localization and mitotic defects in disease models

How do I interpret contradictory results between MPK20 antibody immunoassays and gene expression studies?

When facing discrepancies between antibody detection and gene expression data, consider these analytical approaches:

• Post-transcriptional Regulation: MPK20/KIF20B protein levels may not directly correlate with mRNA expression due to:

  • MicroRNA regulation of translation

  • Protein stability differences across cell types

  • Post-translational modifications affecting antibody epitope recognition

• Methodological Differences:

  • Antibody specificity: Confirm the epitope region recognized by your antibody

  • Cross-reactivity: Test against closely related proteins, especially other MAPK family members

  • Detection thresholds: Protein detection may require signal amplification techniques not needed for sensitive PCR-based gene expression analysis

• Experimental Design Considerations:

  • Temporal dynamics: Gene expression changes may precede detectable protein expression changes

  • Cell heterogeneity: Bulk analysis may mask cell type-specific expression patterns

  • Sub-cellular localization: Protein compartmentalization may affect extraction efficiency and detection

• Resolution Strategies:

  • Perform time-course experiments capturing both transcript and protein levels

  • Use multiple antibodies targeting different epitopes of MPK20/KIF20B

  • Implement single-cell analysis techniques to address cellular heterogeneity

What are the key considerations when designing knockout/knockdown studies to validate MPK20 antibody specificity?

Designing rigorous knockout/knockdown validation experiments for MPK20 antibodies requires attention to:

• Model Selection:

  • For KIF20B studies: Consider whether to use CRISPR-Cas9 knockout or siRNA/shRNA knockdown approaches

  • For plant GhMPK20: Virus-induced gene silencing (VIGS) has been successfully employed

• Validation Metrics:

  • Western blot quantification: Measure reduction in band intensity corresponding to MPK20/KIF20B

  • Immunofluorescence: Confirm reduction/elimination of characteristic staining patterns

  • Functional assays: Verify expected phenotypic changes (e.g., enhanced resistance to F. oxysporum in GhMPK20-silenced cotton)

• Controls and Considerations:

  • Off-target effects: Use multiple siRNAs or guide RNAs targeting different regions

  • Rescue experiments: Reintroduce wild-type protein to confirm phenotype specificity

  • Timing: Account for protein half-life when determining optimal timepoint for analysis after knockdown

• Cross-validation:

  • Use commercial antibodies from different sources targeting different epitopes

  • Combine with gene expression analysis to confirm knockdown at transcript level

  • Consider tagged overexpression systems as positive controls

How should differential MPK20 expression patterns across tissues be interpreted in the context of antibody detection?

The interpretation of tissue-specific MPK20/KIF20B expression patterns requires careful consideration:

• Established Tissue Expression Patterns:

  • The monoclonal antibody 10C7 shows remarkable staining of specific cell subsets in cerebellum, ovary, and testis tissues

  • These tissue-specific expression patterns may reflect specialized functions in these tissues

• Methodological Considerations for Tissue Analysis:

  • Fixation methods significantly impact epitope preservation and detection sensitivity

  • Antigen retrieval protocols may need tissue-specific optimization

  • Background autofluorescence varies across tissues and requires appropriate controls

• Biological Interpretations:

  • Cell type-specific expression may indicate specialized functions

  • Developmental regulation may result in temporal expression differences

  • Cell cycle stage distribution varies across tissues, affecting detection of cell cycle-regulated proteins like KIF20B

• Analytical Approach:

  • Combine immunohistochemistry with in situ hybridization to correlate protein and mRNA localization

  • Perform single-cell analysis when possible to resolve cellular heterogeneity

  • Consider functional studies targeted to specific cell populations where MPK20/KIF20B shows high expression

How can MPK20 antibodies be adapted for use in high-throughput or multiplexed screening applications?

Researchers can leverage MPK20 antibodies in advanced screening applications through these methodological approaches:

• Bead-Based Multiplexed Assays:

  • Addressable Laser Bead Immunoassays (ALBIA) have been established for KIF20B detection

  • Antigens can be coupled to MagPlex microspheres, allowing simultaneous detection of multiple targets

  • Positivity thresholds have been established: >500 MFI for lysates and >250 MFI for synthetic peptides

• High-Content Imaging Applications:

  • Leverage the distinct localization patterns of KIF20B throughout the cell cycle

  • Combine with other cell cycle markers for automated classification of mitotic phases

  • Develop image-analysis algorithms to quantify changes in KIF20B distribution patterns

• Microfluidic Applications:

  • Develop on-chip immunoassays for rapid MPK20/KIF20B detection

  • Combine with single-cell isolation technologies for heterogeneity analysis

  • Implement gradient systems to study response to various stimuli or inhibitors

• Considerations for Assay Development:

  • Antibody orientation and density optimization on solid supports

  • Signal amplification strategies for detecting low-abundance samples

  • Statistical analysis approaches for handling multiplexed dataset complexity

What are the advanced considerations for developing highly specific monoclonal antibodies against MPK20 for specialized research applications?

Developing next-generation MPK20 antibodies requires sophisticated approaches:

• Epitope Selection Strategies:

  • Target unique regions that distinguish MPK20/KIF20B from related proteins

  • The synthetic peptide QPKRAKRKLYTSEISS has proven effective for generating specific monoclonal antibodies against KIF20B

  • Consider regions involved in specific protein-protein interactions or phosphorylation sites for functional studies

• Antibody Engineering Approaches:

  • Develop recombinant antibody formats (scFv, Fab) for improved tissue penetration

  • Consider site-specific conjugation methods for fluorophore or enzyme labeling

  • Explore bispecific formats to simultaneously detect MPK20 and interaction partners

• Validation Requirements:

  • Test against panels of related proteins to confirm specificity

  • Validate across multiple applications (Western blot, immunofluorescence, immunoprecipitation)

  • Perform functional assays to ensure antibodies don't interfere with protein activity

• Advanced Applications:

  • Develop proximity-labeling antibodies to identify novel MPK20 interaction partners

  • Create conformation-specific antibodies to distinguish active vs. inactive states

  • Engineer intracellular antibodies (intrabodies) for live-cell tracking of MPK20